glucose and insulin. The visceral fat level was determined through the non-invasive bioimpedance analysis with an "Omron BF508" scale and body composition monitor. Suicide risk was assessed using Beck Hopelessness Inventory. There were identified two groups of examined: with MetS and without MetS. In both groups were distinguished two subgroups: patients with normal range of hopelessness and patients with mild and moderate hopelessness. Subgroups were compared among themselves for a number of anthropometric, biochemical and clinical indicators. Statistical analysis was conducted using Mann-Whitney U-test. Reliability level corresponded to $p<0.05$. This study was supported by a grant from the Russian Science Foundation 18-15-00011.

Results:

Indicators reflecting the state of carbohydrate and lipid metabolism, body fat composition and symptoms severity in patients with schizophrenia with metabolic syndrome (Me [Q1; Q3])

	Normal range of hopelessness (n = 4)	Mild and moderate level of hopelessness (n = 11)	p-value
Waist circumference	112 [107; 114,5]	101 [97; 105]	**0,026***
Body mass	102,6 [93; 113,8]	86 [83,5; 89,6]	**0,040***
BMI	33,65 [33.3; 34.7]	30,45 [27: 32.5]	**0,010***
Body fat percentage	42 [34,45; 47,9]	34,35 [27,5; 45,9]	**0,412**
Visceral fat level	13,5 [9; 18]	10 [8: 13]	**0,412**
Total fat fold	139,5 [111,5; 155,5]	106 [99; 124]	**0,188**
Abdomen fat fold	49,5 [45,5; 52]	44,5 [38; 47]	**0,240**
Glucose, mmol/L	5,35 [5,15; 6,15]	5,2 [4,9; 5,5]	**0,489**
Ch, mmol/L	5,05 [4,5; 6,02]	4,82 [4,09; 5,5]	**0,661**
TG, mmol/L	2,33 [1,51; 2,9]	1,96 [1,73; 2,17]	**0,753**
HDL, mmol/L	0,73 [0,63; 0,92]	0,64 [0,62;0,8]	**0,661**
LDL, mmol/L	3,12 [2,98; 3,97]	3,32 [2,67; 3,67]	**0,661**
VLDL, mmol/L	1,06 [0,69; 1,32]	0,89 [0,79; 1,07]	**0,851**
AIP	6,43 [4,76; 7,24]	5,65 [4,72; 6,44]	**0,571**

Comment: BMI – body mass index; Ch – cholesterol total; TG - triglycerides; HDL – high density lipoproteins; LDL – low density lipoproteins; VLDL – very low density lipoproteins; AIP – atherogenic index of plasma; p – level of statistical significance of differences

Waist circumference, body weight and BMI in subgroup with normal hopelessness range in the group of patients with MetS were significantly higher (figure 1).

Conclusions: We were able to establish a negative relationship between the waist circumference, body weight and BMI with suicide risk in schizophrenia patients. It can be assumed that adipose tissue can play a "protective" role in the suicidal behavior of schizophrenia patients.

Keywords: suicide risk; schizophrénia; Metabolic syndrome; obesity

EPP1188

Wernicke encephalopathy complicating catatonic schizophrenia

C. Rihab[1], S. Ellouze[1], N. Messedi[2], M. Turki[1,2], F. Ben Ali[1], W. Abid[1], M. Halouani[1] and J. Aloulou[1]

[1]Psychiatry (b), Psychiatry (B), Hedi Chaker University hospital, sfax, Tunisia and [2]Psychiatry (b), Hedi Chaker University hospital, sfax, Tunisia

doi: 10.1192/j.eurpsy.2021.1399

Introduction: Wernicke's encephalopathy is a potentially fatal neurological emergency caused by thiamine deficiency. Although it is often associated with chronic alcoholism, it can also occur in all situations that lead to a thiamine deficiency such as undernutrition and exclusive artificial feeding.

Objectives: In this work, we propose to study the clinical and treatment concerns of Wernicke's encephalopathy complicating catatonic schizophrenia.

Methods: We retrospectively report the case of a patient who developed a Wernicke's encephalopathy in the aftermath of catatonic schizophrenia.

Results: Mr H.L, a 47-year-old-male has been followed in psychiatric hospital since the age of 27 for catatonic schizophrenia. He has been hospitalized in July 2020 because of oral intake refusal, social isolation and lack of self-care with a poor compliance to treatment. Examination of the patient revealed catalepsy, mutism and negativism. He was treated with antipsychotics drugs, benzodiazepines and parenteral nutrition. About six weeks after his hospitalization, the patient developed horizontal nystagmus and ataxic gait. Magnetic resonance imaging was consistent with Wernicke encephalopathy. Vitamin B1 dosage was 32nmol/l. Parenteral thiamine replacement therapy was initiated with clinical improvement

Conclusions: Catatonic schizophrenia can be associated with severe malnutrition and thus with thiamine deficiency and Wernicke's encephalopathy. An early intervention by supplying prophylactic thiamine given parenterally in high-risk patients is crucial to avoid Korsakoff syndrome, as well as cardiovascular and neuropsychiatric complications associated with thiamine deficiency.

Keywords: Wernicke's encephalopathy; catatonic schizophrenia; Korsakoff syndrome

EPP1189

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

Z.B. Dombi[1]*, K. Acsai[1], Á. Barabássy[1], B. Sebe[1], I. Laszlovszky[1], G. Vass[1], B. Szatmári[1], M. Patel[2], W. Earley[3] and G. Németh[1]

[1]Medical Division, Gedeon Richter Plc., Budapest, Hungary; [2]Global Medical Affairs, AbbVie, Madison, United States of America and [3]Clinical Development, AbbVie, Madison, United States of America

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.1400

Introduction: In the early stage of schizophrenia (first 5 years), the most important clinical target besides symptom control is relapse prevention as each relapse significantly decreases the possibility of preferable long-term outcomes. Early discontinuation of antipsychotic medication due to intolerable side-effects is one of the most common causes of relapse.

Objectives: This poster aims to present cariprazine's tolerability in the early stage of schizophrenia.

Methods: Data from 4 randomized, double-blind, placebo-controlled trials (NCT00404573, NCT01104766, NCT01104779, NCT00694707) with similar design (1 week of wash out period, 6 weeks of treatment and 2-4 weeks of follow-up) were pooled. For the post-hoc analysis, patients with early stage of schizophrenia (defined as having a disease duration of less than 5 years) were extracted from the whole safety population, and approved doses of cariprazine (1.5-6.0 mg/day) were combined. Treatment-emergent adverse events (TEAEs) and discontinuation rates were analysed versus placebo.

Results: Overall, 169 placebo- (PBO) and 322 cariprazine-treated (CAR) patients were identified as having schizophrenia for less than 5 years. 67.7% cariprazine- and 56.2% placebo-treated patients reported at least one TEAE; most frequently insomnia (10.9 %

CAR; 12.4% PBO), akathisia (9.6% CAR; 2.4% PBO) and extrapyramidal symptoms (9.3% CAR; 1.8% PBO). Discontinuation due to adverse events was reported in only 8.4% of cariprazine- and 14.8% of placebo-treated patients. Relapse occurred in 3.1% of cariprazine- and 5.3% of placebo-treated patients.
Conclusions: Cariprazine was generally well-tolerated in the early stage of schizophrenia; given the limitations of this analysis, additional research is warranted.

Conflict of interest: Studies were funded by Gedeon Richter Plc. and Allergan Plc (prior to its acquisition by AbbVie). Dombi, Acsai, Dr. Barabássy, Dr. Sebe, Dr. Laszlovszky, Dr Vass, Dr. Szatmári and Dr. Németh are employees of Gedeon Richter Plc., Dr. Earley and Dr. Patel a
Keywords: Cariprazine; schizophrénia; antipsychotic; safety

EPP1190

Neurocognitive function in patients at high risk of schizophrenia with positive thought disorders

I. Fateev[1], M. Omelchenko[1] and I. Pluzhnikov[1,2]*
[1]Department Of Youth Psychiatry, The Mental Health Research Center, Moscow, Russian Federation and [2]Department Of Adult Neuropsychology And Abnormal Psychology, Moscow Institute of Psychoanalysis, Moscow, Russian Federation
*Corresponding author.
doi: 10.1192/j.eurpsy.2021.1401

Introduction: The course of affective disorders varies significantly in clinical practice. There are many symptoms that are not related to affective disorders that cannot be described in other nosologies. In the present study such pathopsychological phenomena similar to psychotic symptoms and related to symptoms of "schizophrenia risk" were designated as positive thought disorders (PTD). These symptoms are understood as manifestations of delusional and hallucinatory register.
Objectives: Aim of the study is to identify and validate the differences of neurocognitive functions among patients with positive thought disorders and at high risk of schizophrenia and patients without thought disorders.
Methods: In the research there were 17 patients with high risk of schizophrenia dominated by PTD (affective disorders, personality disorders, schizophrenic spectrum disorders) and 18 patients without thought disorders (affective disorders, personality disorders) in the research. Patients aged 17-25 years.
Results: According to the results of the The Complex Figure test, the group with a high risk of schizophrenia had significantly low results on the "simultaneity" scale and points for copying the figure (p-value 0.04 and p-value 0.03). According to the results of the Verbal fluency test, the main group had significantly lower indices on the "loss of instruction" scale and on the number of repetitions (p-value 0.021 and p-value 0.009).
Conclusions: In the group of patients with a high risk of schizophrenia with positive thought disorders there are neurocognitive features in the form of reduced inhibitory control and a lack of simultaneity. The most sensitive methods are the Complex figure test and Verbal fluency Test.

Conflict of interest: The reported study was funded by RFBR, project number 20-013-00772
Keywords: Positive thought disorder; high risk of schizophrenia; Neurocognitive function; inhibitory control

EPP1191

Productivity of the performance of visual perceptual tasks and symptom severity in patients with schizotypal disorder

M. Vinogradova[1]*, A. Chepeliuk[1,2] and O. Dorofeeva[2]
[1]Department Of Neuro- And Pathopsychology, Faculty Of Psychology, Lomonosov Moscow State University, Moscow, Russian Federation and [2]Department Of Clinical Psychopharmacology, FSBI "Zakusov Institute of Pharmacology", Moscow, Russian Federation
*Corresponding author.
doi: 10.1192/j.eurpsy.2021.1402

Introduction: The experimental research of visual perceptual processes in schizophrenia could shed a light on the psychological mechanisms of development of the illness.
Objectives: To research the performance of visual perceptual tasks and its correlation with the symptom severity in patients with schizotypal disorder (SD).
Methods: 40 patients with SD in ICD-10 (mean age 29.8±8.3 years) were enrolled to the study. The Positive and Negative Symptoms Scale (PANSS) and two series of visual-perceptual tasks (Figures of Witkin and Goldstein) were applied. In series I subject should make a decision whether a complex figure contains a simple one without any feedback from the experimenter (all 96 trials). In series II each trial included two complex figures presented simultaneously (all 96 trials) that increased the visual-perceptual load. Statistical significance was ascertained by Spearman's rank correlation.
Results: Negative correlations were established between the number of right answers in series II of visual perceptual tasks and emotional withdrawal ($r=-0.78$, $p\leq0.01$), passive/apathetic social withdrawal ($r=-0.53$, $p\leq0.05$). Time of performance of series I and series II had negative correlations with preoccupation ($r=-0.55$ and $r=-0.53$, $p\leq0.05$, respectively).
Conclusions: The decrease in the productivity of visual perceptual tasks performance in case of additional load relates with reduced social and emotional dimensions of symptoms (social initiation, passivity, lack of sociality and inattention in daily activity, etc.) of patients with SD. Impulsivity in solutions (reduction of decision-making time) is associated with the increase of preoccupation with feelings, thoughts and autistic fantasies that lead to social and daily life disadaptation.

Keywords: schizotypal disorder; cognitive processes; visual perceptual tasks

EPP1192

Preliminary analysis of different tools in emotional competence assessment in patients with schizotypal disorder

M. Vinogradova[1]*, O. Khokhlova[1,2], I. Oleichik[3], A. Ermusheva[4] and N. Salikhianova[5]
[1]Department Of Neuro- And Pathopsychology, Faculty Of Psychology, Lomonosov Moscow State University, Moscow, Russian Federation; [2]Psychology Department, Middlesex University Dubai, Dubai, United Arab Emirates; [3]Clinical Department Of Endogenous Mental Disorders And Affective States, Mental Health Research Centre, Moscow, Russian Federation; [4]Department Of Pedagogy And Medical Psychology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation and [5]Department